Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Targeted Therapies and Precision Medicine for Malignant Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Targeted Therapies and Precision Medicine for Malignant Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 3940

Special Issue Editor

Prof. Dr. Anica Dricu

E-Mail Website
Guest Editor
Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: molecular targeted cancer therapy; cancer immunotherapy; biomarkers; stem cells; brain tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the era of personalized medicine, the development of curative cancer therapies is supported by customized treatments concerning a patient's unique biology and metabolism, to ensure the best individualized therapeutic approach is taken. Cancer cells steadily amend gene transcription, translation and post-translational protein modifications to produce and use specific molecules that are essential in the process of growth, proliferation and expansion. When evaluating patients’ response to targeted therapy, genetic, epigenetic, transcriptional, proteomic, metabolic and environmental aspects are considered.

For this Special Issue, we invite original papers, reviews and communications focused on personalized medicine for cancer, including approaches to diagnosis, treatment and prevention that consider genes, proteins, other metabolites, family history, environmental conditions and lifestyles.

Prof. Dr. Anica Dricu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • molecular targeted therapy
  • malignant diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 5159 KiB  
Article
Disruption of the Physical Interaction Between Carbonic Anhydrase IX and the Monocarboxylate Transporter 4 Impacts Lactate Transport in Breast Cancer Cells
by Jacob E. Combs, Akilah B. Murray, Carrie L. Lomelino, Mam Y. Mboge, Mario Mietzsch, Nicole A. Horenstein, Susan C. Frost, Robert McKenna and Holger M. Becker
Int. J. Mol. Sci. 2024, 25(22), 11994; https://doi.org/10.3390/ijms252211994 - 8 Nov 2024
Viewed by 402
Abstract
It has been previously established that breast cancer cells exhibit high expression of the monocarboxylate (lactate) transporters (MCT1 and/or MCT4) and carbonic anhydrase IX (CAIX) and form a functional metabolon for proton-coupled lactate export, thereby stabilizing intracellular pH. CD147 is the MCT accessory [...] Read more.
It has been previously established that breast cancer cells exhibit high expression of the monocarboxylate (lactate) transporters (MCT1 and/or MCT4) and carbonic anhydrase IX (CAIX) and form a functional metabolon for proton-coupled lactate export, thereby stabilizing intracellular pH. CD147 is the MCT accessory protein that facilitates the creation of the MCT/CAIX complex. This study describes how the small molecule Beta-Galactose 2C (BGal2C) blocks the physical and functional interaction between CAIX and either MCT1 or MCT4 in Xenopus oocytes, which reduces the rate of proton and lactate flux with an IC50 of ~90 nM. This value is similar to the Ki for inhibition of CAIX activity. Furthermore, it is shown that BGal2C blocks hypoxia-induced lactate transport in MDA-MB-231 and MCF-7 breast cancer cells, both of which express CAIX. As in oocytes, BGal2C interferes with the physical interaction between CAIX and MCTs in both cell types. Finally, X-ray crystallographic studies highlight unique interactions between BGal2C and a CAIX-mimic that are not observed within the CAII active site and which may underlie the strong specificity of BGal2C for CAIX. These studies demonstrate the utility of a novel sulfonamide in interfering with elevated proton and lactate flux, a hallmark of many solid tumors. Full article
(This article belongs to the Special Issue Molecular Targeted Therapies and Precision Medicine for Malignant Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2126 KiB  
Review
Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions
by Silvia Mara Baez Rodriguez, Ligia Gabriela Tataranu, Amira Kamel, Serban Turliuc, Radu Eugen Rizea and Anica Dricu
Int. J. Mol. Sci. 2024, 25(19), 10765; https://doi.org/10.3390/ijms251910765 - 7 Oct 2024
Viewed by 1455
Abstract
Glioblastoma is known to be one of the most aggressive and fatal human cancers, with a poor prognosis and resistance to standard treatments. In the last few years, many solid tumor treatments have been revolutionized with the help of immunotherapy. However, this type [...] Read more.
Glioblastoma is known to be one of the most aggressive and fatal human cancers, with a poor prognosis and resistance to standard treatments. In the last few years, many solid tumor treatments have been revolutionized with the help of immunotherapy. However, this type of treatment has failed to improve the results in glioblastoma patients. Effective immunotherapeutic strategies may be developed after understanding how glioblastoma achieves tumor-mediated immune suppression in both local and systemic landscapes. Biomarkers may help identify patients most likely to benefit from this type of treatment. In this review, we discuss the use of immunotherapy in glioblastoma, with an emphasis on immune checkpoint inhibitors and the factors that influence clinical response. A Pubmed data search was performed for all existing information regarding immune checkpoint inhibitors used for the treatment of glioblastoma. All data evaluating the ongoing clinical trials involving the use of ICIs either as monotherapy or in combination with other drugs was compiled and analyzed. Full article
(This article belongs to the Special Issue Molecular Targeted Therapies and Precision Medicine for Malignant Diseases)
►▼ Show Figures

Figure 1

13 pages, 1181 KiB  
Review
Modifications of Nanobubble Therapy for Cancer Treatment
by Katarzyna M. Terlikowska, Bozena Dobrzycka and Slawomir J. Terlikowski
Int. J. Mol. Sci. 2024, 25(13), 7292; https://doi.org/10.3390/ijms25137292 - 2 Jul 2024
Viewed by 1483
Abstract
Cancer development is related to genetic mutations in primary cells, where 5–10% of all cancers are derived from acquired genetic defects, most of which are a consequence of the environment and lifestyle. As it turns out, over half of cancer deaths are due [...] Read more.
Cancer development is related to genetic mutations in primary cells, where 5–10% of all cancers are derived from acquired genetic defects, most of which are a consequence of the environment and lifestyle. As it turns out, over half of cancer deaths are due to the generation of drug resistance. The local delivery of chemotherapeutic drugs may reduce their toxicity by increasing their therapeutic dose at targeted sites and by decreasing the plasma levels of circulating drugs. Nanobubbles have attracted much attention as an effective drug distribution system due to their non-invasiveness and targetability. This review aims to present the characteristics of nanobubble systems and their efficacy within the biomedical field with special emphasis on cancer treatment. In vivo and in vitro studies on cancer confirm nanobubbles’ ability and good blood capillary perfusion; however, there is a need to define their safety and side effects in clinical trials. Full article
(This article belongs to the Special Issue Molecular Targeted Therapies and Precision Medicine for Malignant Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop